POSB23 Tafasitamab Plus Lenalidomide (T-L) Versus Standard of Care (SoC) Including 3 Rituximab-Based Treatments or Lenalidomide Monotherapy in Patients with Non-Transplant Eligible Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NTE R/R DLBCL): A Matching Adjusted Indirect Treatment Comparison (MAIC)

Saved in:
Bibliographic Details
Published inValue in health Vol. 25; no. 1; p. S29
Main Authors Córdoba, R, Prawitz, T, Westley, T, Sharma, A, Kapetanakis, V, Sabatelli, L
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.01.2022
Online AccessGet full text

Cover

More Information
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2021.11.133